A Phase 1/2 interventional study of NPI-002 Intravitreal Implant in Cataract, sponsored by Nacuity Pharmaceuticals, Inc.. Completed at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Nacuity Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Cataract with a site in Australia — 2 open to participants now, 3 under way, none of them phase 3. Cataract · Australia.
Among the 17 studies in Cataract with a site in Australia, this one is the 11th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2022, is the only one in phase 1/2, and was the 11th registered.
1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.
Browse Cataract studies →2 of the 17 studies in Cataract with a site in Australia are open now. Recruiting first, the newest first:
Alcon Research · Sites in Australia, India, Philippines
Ages 22+
The Hong Kong Polytechnic University · Sites in Australia, China, Hong Kong
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 1 · Phase 3 1
First in 2007; this study’s year is marked. 1 started in 2022.
This study's enrollment of 24 is below the median of 79 across 1,094 interventional studies indexed under Cataract.
Median enrollment 93 across the 14 interventional studies, 307 across the 3 observational. Of the 13 that completed or were terminated, 6 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 17 have an industry lead sponsor. The 9 most frequent:
Nacuity Pharmaceuticals, Inc. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Nacuity Pharmaceuticals, Inc. has 1 study filed under Cataract — fewer than ten, so there is no comparison to draw.
2 of the studies in Cataract with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07733154The Hong Kong Polytechnic UniversityAI-Driven IOL Prediction Using SS-OCT Biometry | 2027-03-20 |
| NCT07587138Alcon ResearchClinical Evaluation of a Novel Trifocal IOL | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Cataract with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will examine the safety and efficacy NPI-002 intravitreal implants post vitrectomy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
one NPI-002 implant inserted at the time of vitrectomy
Drug: NPI-002 Intravitreal Implant
two NPI-002 implants inserted at the time of vitrectomy
Drug: NPI-002 Intravitreal Implant
No implant inserted at time of vitrectomy
Implant inserted during vitrectomy.
Lens Densitometry
Change from Baseline
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2022 to primary completion in Sep 2026, 55 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nacuity Pharmaceuticals, Inc.